Inside Eli Lilly’s new weight‑loss drug
Digest more
The proposal could affect telehealth services that rely on outside facilities to produce the knockoff drugs in bulk.
If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear ...
FDA seeks restrict compounding of GLP-1 drugs by excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list to limit unauthorized use.
In Canada, health regulators took one step to fill that gap by approving a generic version of semaglutide, which is the ...
The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, effectively ending ...
FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of ...
Most compounded versions of popular drugs used for weight loss including Wegovy and Zepbound may soon no longer be available after a U.S. judge declined an initial injunction to allow ...
The US Food and Drug Administration (FDA) late Friday issued revised versions of two final guidance documents explaining the use of bulk drug substances in compounding and clarifying that the ...
Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results